Sept 17 (Reuters) - United Therapeutics Corp UTHR.O :
* UNITED THERAPEUTICS - SAMUMED, CO ANNOUNCE NORTH AMERICAN LICENSE AGREEMENT FOR SAMUMED'S IPF DRUG CANDIDATE
* UNITED THERAPEUTICS - DEAL TERMS INCLUDE $10 MILLION UP-FRONT, PLUS UP TO $340 MILLION IN DEVELOPMENTAL MILESTONES AND UP TO LOW DOUBLE-DIGIT ROYALTIES
* UNITED THERAPEUTICS CORP - DEAL TERMS INCLUDE $10 MILLION UP-FRONT, PLUS UP TO $340 MILLION IN DEVELOPMENTAL MILESTONES AND UP TO LOW DOUBLE-DIGIT ROYALTIES
* UNITED THERAPEUTICS - UNDER TERMS, UNIT OF CO WILL CONDUCT, FUND ALL FURTHER DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES IN U.S. & CANADA
* UNITED THERAPEUTICS - SAMUMED RETAINS DEVELOPMENT AND COMMERCIALIZATION RIGHTS FOR ALL MARKETS OUTSIDE OF NORTH AMERICA